Investors

• 10: BioPorto completes the subscription of convertible bonds
• 09: Subscription and issue of convertible bonds
• 08: Interim Financial Report for Q2 2010
• 07: BioPorto’s NGAL test approved for use by leading U.S. reference laboratory
• 06: BioPorto’s patent rights for NGAL - opposition to the European patent
• Newsletter July 2010
• 05: Interim financial report Q1
• 04: Development of Annual General Meeting
• 03: Insider's dealings
• 02: Annual General Meeting
• 01: Annual Report 2009
• Newsletter January 2010
• 29: Financial calendar 2010
• 28: Interim financial report for Q3 2009
• 27: Share Capital and Votes
• 26: EPO decides to issue BioPorto’s NGAL cutoff patent on November 11, 2009
• 25: Company articles
• 24: BioPorto completes cash issue
• 23: CCH drops lawsuit
• 22: Cash issue, private placement
• 21: Interim Financial Report for Q2 2009
• Documentation: EPO's reply to 3rd party
• 20: BioPorto adopts new rapid route to widespread commercialization of kidney test
• 19: EPO maintains October 1, 2009, as the date of resumption of patent grant proceedings
• 18: Objections from CCH against the resumption of grant proceedings
• 17: Insider's dealings
• 16: Insider's dealings
• 15: Insider's dealings
• 14: Interim financial report for Q1
• 13: Change of date for resumption
• 12: Resumption of proceedings for BioPorto's patent
• 11: Issue of warrants in BioPorto A/S
• 10: Insider's dealings
• 09: Development of annual general meeting
• 08: Insider's dealings
• 07: Insider's dealings
• 06: Insider's dealings
• 05: Insider's dealings
• 04: Annual General Meeting
• 03: Launch of APC-PCI ELISA Kit
• 02: Annual Report 2008
• 01: BioPorto's cutoff patent for NGAL – grant proceedings stayed